Business
Zhongchao Inc. Expands Patient Management Business to Ovarian Cancer Market
SHANGHAI, Aug. 25, 2021 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare
About this update from Zhongchao Inc.
[{"type":"text","content":"SHANGHAI, Aug. 25, 2021 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management platform, today announced its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd. (\"Zhongxin\") provides patient follow-up management services for ovarian cancer patients from Zeyoulexiang Patient Assistance Project (the \"Project\"), helping ovarian cancer patients improve treatment outcomes and eventually increase survival rate. \nThe Project, managed by Bethune Charitable Foundation, provides assistance to female patients in mainland China who meet the standards to take Niraparib, an anti-cancer medication. Through the all-in-one patient management system (\"All-in-One System\") developed by the Company, patients can record, track and view various indications of their bodies and disease during the medication and receive early warnings of potential disease progression to manage adverse reactions and psychological problems during medication and improve their adherence to treatment and treatment safety. In addition, the digital follow-up function embedded in the All-in-One System allows patient management specialists and physicians to provide one-on-one medication guidance and lifestyle advice for patients to ensure correct drugs usage and response to adverse reactions, improving the treatment experience.\nThe Project consists of a service network of more than 350 hospitals, 40 pharmacies, and 1,000 physicians, supported by the All-in-One System operated by Zhongxin, and is jointly supported and assisted by Cancer Hospital Chinese Academy of Medical Sciences, Beijing Obstetrics Gynecology Hospital, Peking Union Medical College Hospital, Beijing Cancer Hospital, Zhongshan Hospital of Fudan University, and Red House Hospital. As of July 2021, more than 5,000 ovarian cancer patients had received drug assistance and patient management services through the Project.\nAccording to GlobalData, the ovarian cancer market was valued at $1.8 billion in 2018 across the seven major markets, including the USA, France, Germany, Italy, Spain, UK and Japan, and it is expected to grow to $6.7 billion in the next ten years with a compound annual grow...